A Study in Adolescent and Adult Female Participants to Evaluate Clinical Symptom Improvement and the Safety of Gepotidacin During Treatment of Uncomplicated Urinary Tract Infections (Acute Cystitis)

PHASE3CompletedINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

October 2, 2024

Primary Completion Date

March 10, 2025

Study Completion Date

March 10, 2025

Conditions
Urinary Tract Infections
Interventions
DRUG

Gepotidacin

Gepotidacin will be administered.

Trial Locations (22)

26501

GSK Investigational Site, Morgantown

26537

GSK Investigational Site, Kingwood

33135

GSK Investigational Site, Miami

33461

GSK Investigational Site, Palm Springs

45424

GSK Investigational Site, Dayton

75149

GSK Investigational Site, Mesquite

77036

GSK Investigational Site, Houston

77087

GSK Investigational Site, Houston

91355

GSK Investigational Site, Valencia

95350-5365

GSK Investigational Site, Modesto

91101-2453

GSK Investigational Site, Pasadena

92120-5259

GSK Investigational Site, San Diego

32174-6302

GSK Investigational Site, Ormond Beach

33406-7671

GSK Investigational Site, Palm Springs

33563-4202

GSK Investigational Site, Plant City

33172-2741

GSK Investigational Site, Sweetwater

33409-3401

GSK Investigational Site, West Palm Beach

07093-2622

GSK Investigational Site, West New York

10016-7313

GSK Investigational Site, New York

75126-4174

GSK Investigational Site, Forney

77459-4756

GSK Investigational Site, Missouri City

84010-4943

GSK Investigational Site, Bountiful

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT06597344 - A Study in Adolescent and Adult Female Participants to Evaluate Clinical Symptom Improvement and the Safety of Gepotidacin During Treatment of Uncomplicated Urinary Tract Infections (Acute Cystitis) | Biotech Hunter | Biotech Hunter